肾移植受者BK多瘤病毒肾病的临床试验共识定义
肾移植受者BK多瘤病毒感染和BK多瘤病毒肾病是移植物功能障碍和过早失功的重要原因。为促进临床试验终点一致并支持临床研究与药物开发,移植相关病毒感染论坛BK疾病定义工作组与协作研究论坛(由科学家、临床医生、监管人员和行业代表组成)制定了BKPyV感染和疾病的定义。这些定义细化了「确诊」BKPyV疾病的原则,并引入「可能」疾病类别,可用于预防或治疗肾移植受者BKPyVAN的临床试验。
要点
- BKPyV感染和BKPyVAN是肾移植受者移植物功能障碍和过早失功的重要原因。
- 定义由移植相关病毒感染论坛BK疾病定义工作组与协作研究论坛制定。
- 引入「可能」疾病类别,可用于预防或治疗BKPyVAN的临床试验。
核心结论
- 这些定义细化了「确诊」BKPyV疾病的原则,并引入「可能」疾病类别,可用于预防或治疗肾移植受者BKPyVAN的临床试验。
研究设计与样本
- 定义由移植相关病毒感染论坛BK疾病定义工作组与协作研究论坛制定,工作组由科学家、临床医生、监管人员和行业代表组成。
主要发现
- 评估预防和治疗新药的对照临床试验是必要的,但缺乏能准确评估干预效果、具有临床相关性且从监管角度可接受的结果指标,阻碍了此类试验。
关键数值与推荐
- 细化「确诊」BKPyV疾病的原则并引入「可能」疾病类别,用于预防或治疗BKPyVAN的临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: BK polyomavirus (BKPyV) infection and BK polyomavirus nephropathy (BKPyVAN) are important causes of allograft dysfunction and premature allograft loss in renal transplant recipients. RESULTS AND DISCUSSION: Controlled clinical trials to evaluate new agents for prevention and treatment are needed but are hampered by the lack of outcome measures that accurately assess the effect of the intervention, are clinically relevant, and are acceptable from a regulatory perspective. METHODS: To facilitate consistent end points in clinical trials and to support clinical research and drug development, definitions of BKPyV infection and disease have been developed by the BK Disease Definitions Working Group of the Transplantation Associated Virus Infection Forum with the Forum for Collaborative Research, which consists of scientists, clinicians, regulators, and industry representatives. CONCLUSIONS: These definitions refine established principles of "proven" BKPyV disease and introduce a "probable" disease category that could be used in clinical trials to prevent or treat BKPyVAN in renal transplant recipients.
引用
- Imlay H, Baum P, Brennan DC, et al. Consensus Definitions of BK Polyomavirus Nephropathy in Renal Transplant Recipients for Clinical Trials. Clin Infect Dis. 2022. PMID: 35100619. doi:10.1093/cid/ciac071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。